Founders Capital Management (Texas)’s Ocular Therapeutix OCUL Stock Holding History

Founders Capital Management (Texas)’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.2K	Buy	2,500 +500	+25%	+$4.76K	0.01%	241
2025 Q4	$24.3K	Hold	2,000	–	–	0.01%	224
2025 Q3	$23.4K	Hold	2,000	–	–	0.01%	226
2025 Q2	$18.6K	Hold	2,000	–	–	0.01%	238
2025 Q1	$14.7K	Hold	2,000	–	–	0.01%	251
2024 Q4	$17.1K	Hold	2,000	–	–	0.01%	240
2024 Q3	$17.4K	Hold	2,000	–	–	0.01%	248
2024 Q2	$13.7K	Hold	2,000	–	–	0.01%	264
2024 Q1	$18.2K	Hold	2,000	–	–	0.01%	241
2023 Q4	$8.92K	Sell	2,000 -1,500	-43%	-$4.44K	0.01%	296
2023 Q3	$11K	Hold	3,500	–	–	0.01%	288
2023 Q2	$18.1K	Hold	3,500	–	–	0.01%	248
2023 Q1	$18K	Buy	3,500 +1,000	+40%	+$4.75K	0.01%	248
2022 Q4	$7K	Hold	2,500	–	–	0.01%	325
2022 Q3	$10K	Hold	2,500	–	–	0.01%	298
2022 Q2	$10K	Buy	+2,500	New	+$9.44K	0.01%	309

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Founders Capital Management (Texas)'s OCUL Position: Q1 2026 in Review

Founders Capital Management (Texas) increased its Ocular Therapeutix (OCUL) stake by 25% in Q1 2026, buying an estimated $4.76K and bringing the position to 2,500 shares worth $21.2K. The position accounts for 0.01% of the portfolio, ranked #241.

Founders Capital Management (Texas) first reported a position in OCUL in Q2 2022 and has held it in 16 quarters since. The position peaked at $24.3K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Founders Capital Management (Texas) held 2,500 shares of Ocular Therapeutix worth $21.2K as of Q1 2026.
Founders Capital Management (Texas) bought 500 Ocular Therapeutix shares in Q1 2026, an estimated $4.76K.
Ocular Therapeutix made up 0.01% of Founders Capital Management (Texas)'s portfolio in Q1 2026, its #241 holding.
Founders Capital Management (Texas) first reported a position in Ocular Therapeutix in Q2 2022 and has held it in 16 quarters since.
Founders Capital Management (Texas)'s Ocular Therapeutix position peaked at $24.3K in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q1 2026, filed 21 Apr 2026.